The global Cell Therapy Technologies market is expected to grow at a CAGR of around 14.3% from 2020 to 2027 and expected to reach the market value of around US$ 6.5 Bn by 2027.
Cell therapy is the incorporation of intact, live cells into a patients' body to assist in curing or lessen the spread of disease. The cells used in cell therapy are classified based on their capability of transformation into different cell types. In May 2019, AveXis, a Novartis company announced that the US Food and Drug Administration (FDA) approved Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age suffering from spinal muscular atrophy (SMA). Additionally, in July 2020, the USFDA approved Tecartus (brexucabtagene autoleucel), cell-based therapy for the treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who failed to respond or have fallen for other kinds of treatment. Tecartus, is the chimeric antigen receptor (CAR) T cell therapy is the first cell-based therapy approved by the FDA for the treatment of MCL.
Market Driver and Trends
Big calls for "Stem cell therapy"
As per the Australian government, Department of Health, Stem cell therapy is a proven treatment for the treatment of blood disorders such as leukemia, Hodgkin's diseases, and non-Hodgkin's lymphoma. Stem cells possess the capability to treat many other types of incurable diseases. The self-eating process of stem cells is a new gateway to regenerative medicines. In July 2020, Penn Medicine, Philadelphia, commented that the self-eating process in embryonic stem cells known as chaperone-mediated autophagy (CMA) and a related metabolite can serve as a promising new therapeutic target to repair or regenerate damaged cells and organs. The new preclinical study in the first phase shows that the stem cells keep chaperone-mediated autophagy (CMA) at low levels promoting self-renewal and when the stem cell gets matured or ready it switches its suppression off to enhance CMA among other activities and differentiate into specialized cells. Such newly discovered role of autophagy in the stem cells is the beginning of further investigations that enhance researchers and physician-scientists to introduce better therapies and treat various disorders.
Are stem cells a solution to tackle the COVID-19 pandemic?
Stem cells can prove the best solution against the COVID-19 pandemic. Currently, 17 clinical trials evaluate the therapeutic potential of Mesenchymal Stem Cells (MSCs) for the treatment of COVID-19; the majority is administered intravenously with one clinical trial testing MSC-derived exosomes via the inhalation route. MSCs could be a promising treatment for COVID-19 infections. Since the key for treatment of COVID-19 lies in the management of the cytokine storm in the lungs, MSCs acts as a proper fit considering the mechanisms of action (MOA) is through immunomodulatory and anti-inflammatory associated properties. Other types of stem cells investigated for the treatment of COVID-19 infections involve genetically engineered human induced pluripotent stem cells. Regardless of the urgency for the need for MSCs based therapies for COVID-19, the production of MSCs must stand in compliance with good manufacturing practices (GMP) and regulations before getting approved in humans.
The cell therapy technologies market is based on the product, cell type, process, and end-user. By product, the cell therapy technologies market is segmented as consumables, equipment, and systems & software. By cell type, it is segregated as T-cells, stem cells, and other cells. Cell therapy technologies market by the process is segmented as cell processing, cell preservation, distribution and handling, and process monitoring, and quality control. End-user is further bifurcated into biopharmaceutical & biotechnology companies and contract research organizations (CROs) and research institutes and cell banks.
Consumables projected to hold the largest market share for cell therapy technologies market
The consumables segment accounted largest market share in the past and is expected to continue the same trend in the forthcoming years. Factors that contribute to the growth of the segment involve rising investments for the development of advanced products and high government involvement for enhancing cell based research contribute fullest for the growth. Cell and gene therapy platform (C & GT) drives the science through the breakdown of innovative treatment for patients/new platform accelerates strategically all activities coupled with the value chain. In December 2020, Bayer AG announced the launching of a new cell and Gene therapy (C & GT) platform within its pharmaceutical division. Strategically, Bayer focuses on selected areas of C & GT such as stem cell therapies (with a focus on induced pluripotent cells or iPSCs), gene augmentation, gene editing, and allogeneic cell therapies in different indications. In November 2020, the Government of Canada and JDRF announced new research funding that accelerates stem cell based therapies for type 1 diabetes. In Canada, more than 300,000 Canadians are living with type 1 diabetes (T1D), an autoimmune disease resulting in the dysfunction, damage, or loss of pancreatic beta cells that produce insulin in the body. The Minister of Health announced an investment of US$ 6 Mn through the CIHR-JDRF Partnership to Defeat Diabetes.
Based on cell type, T-cells will record the highest revenue in the global cell therapy technologies market
In 2019, T-cells accounted for the largest share of the Cell Therapy Technologies market. Rising demand for T-cell therapies and favorable government initiatives are the factors that bolster the growth of this segment. As T-cell therapy possess vast application such as therapy for boosting immunity system for the patients suffering from chronic diseases. Moreover, the growing occurrence of cancer globally has gained strong attention for T-cell therapy across the population. CAR T- cell therapy utilizes (CAR T), a patient’s immune cells that are re-programmed to recognize and kill cancer cells throughout the body. The process involves the removal of some T-cells from a patient, and through the laboratory process, these T-cells are re-programmed to identify patient cancer cells. For the patients suffering from leukemia and lymphoma, the T-cells therapies are currently being tested in clinical trials that seem to work well in the presence of a relatively small number of cells. For patients carrying solid tumors such as breast, lung, or pancreatic cancer, therapies require multiple doses of potent cells to reach and attack effectively against the tumors. There are undergoing studies for T-cell therapies for solid tumors.
Cell processing is growing tremendously
The cell processing segment dominated the market in the past and will have a positive influence in the coming years. This segment will record the highest CAGR in the analysis tenure. One of the prominent factors that contribute to the growth of the cell processing segment is that cell processing utilizes efficient cell therapy instruments and media, especially during culture media processing techniques. This acts positively for recording the largest growth of the segment in the worldwide market. With 675 clinical trials are underway worldwide for cell therapy and cell-based immune-oncology as per the record in mid-2020 released by the Alliance for Regenerative Medicine, there are yet few cell therapies in development that become commercially available. During cell processing there are several factors to be considered such as safety and efficacy, transferring to manufacturing processes, lack of scalability, high cost of facilities, labor and equipment, and complexities associated with the processes involved. To avoid this manufacturers focus on the development of new techniques to counterattack such problems. For instance, in October 2020, Thermo Fisher Scientific announced the launching of a closed system for cell therapy manufacturing. Thermo Fisher Scientific launching of Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed-cell therapy processing system acts as a solution to the problem. The device is scalable, cost-effective, cell therapy development and manufacturing. The device is specialized in facilitating workflows from research through good manufacturing practices (GMP) clinical development and commercial manufacturing.
North America registered the largest market share for Cell Therapy Technologies market globally. In the past, North America registered a commendable largest share for Cell Therapy Technologies market. This can be attributed to the rising prevalence of chronic diseases, rising healthcare expenditure, growing disposable incomes, growing healthcare awareness, and the availability of technologically advanced devices in the North American regional market.
Key companies profiled in this report involve Terumo BCT Inc., STEMCELL Technologies Inc., Thermo Fisher Scientific, Beckman Coulter, Lonza Group AG, Miltenyi Biotec, Merck KGaA, and GE Healthcare among others.
Market By Product
Systems & Software
Market By Cell Type
Market By Cell Processing
Cell Preservation, Distribution, and Handling
Process Monitoring and Quality Control
Market By End User
Biopharmaceutical & Biotechnology Companies and CROs
Research Institutes and Cell Banks
Market By Geography
Middle East & Africa
The Cell Therapy Technologies is expected to reach a market value of around US$ 6.5 Bn by 2027.
The Cell Therapy Technologies market is expected to grow at a CAGR of around 14.3% from 2020 to 2027.
Consumables, is the leading segment in the overall Cell Therapy Technologies market.
Rising government initiatives and high focus on personalized medicines are the prominent factors that boost the demand for Cell Therapy Technologies market.
Terumo BCT Inc. Inc., STEMCELL Technologies Inc., Thermo Fisher Scientific, Beckman Coulter, Lonza Group AG Group AG, Miltenyi Biotec, Merck Group, and GE Healthcare among others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years